Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

54.45 +0.26 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,870,038
Open 54.71
Bid (Size) 53.27 (1)
Ask (Size) 55.00 (5)
Prev. Close 54.19
Today's Range 54.42 - 54.74
52wk Range 36.91 - 58.10
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat

Performance

YTD
+11.12%
+11.12%
1 Month
+13.79%
+13.79%
3 Month
+13.15%
+13.15%
6 Month
+46.29%
+46.29%
1 Year
+5.05%
+5.05%

More News

Read More
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
Via The Motley Fool
Is Sanofi Stock a Buy Now?
Via The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
Via Investor's Business Daily
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action
Via Investor Brand Network
Why Shares of Regeneron Are Rising Thursday
Via The Motley Fool
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Via Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Via Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
Via Investor's Business Daily
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Via Benzinga
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Via Benzinga
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
Via The Motley Fool
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
Via Investor's Business Daily
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories
Via Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
Why Provention Bio Stock Skyrocketed 256% This Week
Via The Motley Fool
What's Going On With Sanofi Stock After Hours?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.